FP7Реинтеграция2011–2014

GENTOPHEN · Linking genotype to phenotype for the rheumatoid arthritis susceptibility locus 6q23: beyond genome wide association studies

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2011-03-01 → 2014-02-28
Финансиране от ЕС
45 000 €
Участници
1
Схема
MC-ERG

Линиите свързват координатора с партньорите.

Накратко на български

Генетичните вариации в определен участък от ДНК се анализират, за да се разбере как те влияят върху работата на протеина TNFAIP3 при ревматоиден артрит. Това помага да се установи механизмът, по който конкретни наследствени промени предразполагат организма към развитие на това заболяване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Linking genotype to phenotype for the rheumatoid arthritis susceptibility locus 6q23: beyond genome wide association studies

Genome wide association studies have been extremely successful in identifying regions of the genome that predispose to rheumatoid arthritis (RA). However, for the majority of these disease loci, the genes responsible for the predisposition have not been identified yet. The majority of associated variants map outside coding regions, so their impact on phenotype might be the result of an ability to differentially regulate gene expression. An intergenic region upstream TNFAIP3 is one of the most important loci in RA. My work aims to investigate the mechanism by which variation in this region predisposes to RA. rs6920220 is the most strongly associated variant in the locus and is in perfect linkage disequilibrium (LD) with 7 other SNPs. Among them, Bioinformatics searches indicated that rs6927172 shows more evidence of regulatory activity. Therefore, I prioritized this variant for functional studies. I tested whether rs6927172 was associated with impaired expression of TNFAIP3, but found no differences in mRNA levels between individuals carrying the different alleles of the variant in blood. However, I am now testing whether TNFAIP3 expression is modulated by the SNP in isolated primary cell types. I detected differential protein binding to the SNP using electrophoretic mobility shift assays (EMSA). Bioinformatics searches predicted binding of NFkB, an important mediator of RA pathogenesis, so antibodies against this transcription factor were used in chromatin immunoprecipitation studies to test whether the predicted binding occurred and whether there are allele specific differences in the binding. Preliminary data shows an increase in NFkB binding in cells carrying the risk allele. Hence, the intergenic associated region shows evidence of transcriptional regulatory activity, but as it lies at a large distance from any gene, I am using a modification of the chromosome conformation capture technique to test whether the associated variant physically interacts with TNFAIP3 when the DNA assumes its natural 3D conformation. Preliminary data shows that the promoter of TNFAIP3 interacts with a 5’ intergenic region in close proximity to the RA associated SNPs and also with a 3’ intergenic region where additional SNPs associated with RA map. These results suggest that rs6927172 is a functional causal variant in the TNFAIP3 loci, by impaired regulation of TNFAIP3 expression through physical interaction with the gene promoter and altered binding of NFkB. One of the major goals of the field of complex diseases genetics is to identify the specific genetic variants from a risk-associated locus that accounts for phenotypic differences based on the functional biology it modulates. The work carried out during my MC-ERG is aimed at developing a strategy to identify causal variants and genes in intergenic disease associated regions, and therefore represents advancement beyond the state-of-the-art in the field and has the potential to have a wider impact in the unravelling of the causes of complex diseases. My MC-ERG has helped me obtain a prestigious Wellcome Trust Research Career Development Fellowship which will have a great impact in my future career and boost my opportunities to secure further funding.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Rheumatoid arthritis (RA) is a chronic, disabling, complex autoimmune disease with a strong genetic component. After the well known HLA-DRB1 and PTPN22 genetic loci, the next most strongly associated locus is an intergenic region on 6q23, 180 Kb from the candidate gene TNFAIP3. The causal variants and their functional effects have not been identified yet. The aim of this project is to identify all causal variants in the region and determine how they function to increase RA risk.The first step will be to understand the complete genetic architecture of the locus. I will use data from in-depth fine mapping and resequencing studies of the region, followed by case-control association studies to identify all associated variants including common and rare SNPs, CNVs and indels. Bioinformatic analysis will help to prioritize variants for subsequent functional characterization and will guide the design of experiments. Complementary to that, cDNA sequencing of the region will be undertaken to explore whether the intergenic region is truly noncoding or whether any hitherto undetected transcriptional activity is present. This will allow me to simultaneously determine the effect of different SNP alleles on the levels of expression by allele differential expression measurement.Since associated variants map a considerable distance from the candidate gene, I will test whether distant regulatory elements lie at the site of disease variants through chromosome conformation capture. Finally the mechanism by which variants disrupt transcriptional regulation will be elucidated by performing formaldehyde-assisted isolation of regulatory elements and chromatin immunoprecipitation.The outcome will be the identification of all causal variants in 6q23 and the elucidation of their functional role in the predisposition to RA. This will help to understand the aetiology of RA and autoimmunity and, potentially, to develop new therapeutic targets.""

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз